Orexigen buys back $35 million of 2.75% convertibles due 2020 at 28.25

By Marisa Wong

Morgantown, W.Va., Dec. 30 – Orexigen Therapeutics, Inc. repurchased $35 million of its 2.75% convertible senior notes due 2020 for about $10 million, according to an 8-K filing with the Securities and Exchange Commission.

The settlement amount corresponded to an effective purchase price of 28.25.

San Diego-based Orexigen is a biopharmaceutical company focused on development of treatments of obesity.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.